New appointment at TorreyPines
This article was originally published in Scrip
TorreyPines Therapeutics (US) has appointed Evelyn Graham chief executive officer and a member of the company's board of directors. Ms Graham has served as acting CEO since September 1st.
You may also be interested in...
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.
The sellers of the anti-aging “cure-all” reached an agreement with the FTC in February that prohibits them from making false and unsubstantiated health claims and requires them to pay $660,000 in total to the Commission. Refund checks now are being issued to more than 1,300 defrauded consumers.